Working... Menu

Clinical Evaluation of Toric Intraocular Lens

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03242486
Recruitment Status : Completed
First Posted : August 8, 2017
Last Update Posted : February 20, 2018
Information provided by (Responsible Party):
Nidek Co. LTD.

Brief Summary:
Evaluate efficacy and safety of the toric IOL implanted into aphakic eye with corneal astigmatism after cataract surgery.

Condition or disease Intervention/treatment Phase
Cataract Astigmatism Device: toric intraocular lens Not Applicable

Detailed Description:


  • primary endpoint is visual acuity with pre-determined spherical correction.
  • secondary endpoint is UCVA with spherical correction, BSCVA, Refractive Cylinder Correction, Spherical Equivalent, IOL rotation


  • number and percentage of adverse event

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Effectiveness Evaluation of Toric Intraocular Lens
Actual Study Start Date : December 2014
Actual Primary Completion Date : May 2017
Actual Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Experimental: toric intraocular lens
toric intraocular lens is implanted to all subjects
Device: toric intraocular lens

Primary Outcome Measures :
  1. Visual acuity [ Time Frame: postoperative 6 months ]
    Visual acuity with pre-determined spherical correction

Secondary Outcome Measures :
  1. Visual acuity [ Time Frame: postoperative 6 months ]
    UCVA with spherical correction, BSCVA, Refractive Cylinder Correction, Spherical Equivalent

  2. IOL rotation [ Time Frame: postoperative 6 months ]
    angle of rotation

Other Outcome Measures:
  1. Adverse events [ Time Frame: one year ]
    Severity and causal relationship

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with age of 40 years or older
  • Patients with age-related cataract in one eye or both eyes.
  • Patients willing to participate in the required postoperative study.
  • Patient who can understand and sign the consent document.
  • An eye whose pupil diameter after mydriasis is 5 mm or greater.
  • An eye whose preoperative corneal cylindrical power is 1.0D or more.
  • An eye whose postoperative astigmatism is predicted to be less than 0.5 D.
  • An eye whose postoperative visual acuity with spherical addition is 0.8 D or more.

Exclusion Criteria:

  • Disorder of corneal endothelium
  • Uncontrolled glaucoma
  • Active Uveitis
  • Diabetic retinopathy
  • Retinal detachment
  • Congenital ocular anomalies
  • Choroidal hemorrhage
  • Shallow anterior chamber
  • Microphthalmus
  • Corneal dystrophy
  • Optic atrophy
  • Ocular hypertension
  • Amblyopia
  • Previous history of corneal transplantation
  • Active Iritis
  • Corneal disorder
  • Macular degeneration
  • Retinal degeneration
  • Clinically significant change in macula and/or retinal pigment epithelium
  • Corneal irregular astigmatism
  • Atopic disease
  • Brittleness of Zinn's zonule, fractured zonule and lens luxation (including subluxation)
  • Pseudo-exfoliation syndrome
  • Iris neovascularization
  • Long axis length eye (axis length : 28mm or more)
  • Severe dry eye, abnormality of the lens surface
  • Concurrent participation in another drug and device clinical investigation
  • Patient with mental deficiency or psychiatric disorder and/or who is not capable of expressing the consent of participating in the trial
  • Patient who is judged inappropriate by investigators or sub-investigators

Layout table for additonal information
Responsible Party: Nidek Co. LTD. Identifier: NCT03242486     History of Changes
Other Study ID Numbers: TIOL-YST
First Posted: August 8, 2017    Key Record Dates
Last Update Posted: February 20, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lens Diseases
Eye Diseases
Refractive Errors